Edesa Biotech Reports Dermatitis Study Enrolling Faster than Expected

Author's Avatar
Apr 28, 2022
  • Completion of enrollment is anticipated by calendar fourth quarter for the Phase 2b study of Edesa's potentially first-in-class, anti-inflammatory drug